

Gary M K Tse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6895980/publications.pdf>

Version: 2024-02-01

157
papers

7,139
citations

87401

40
h-index

75989

78
g-index

163
all docs

163
docs citations

163
times ranked

10933
citing authors

#	ARTICLE	IF	CITATIONS
1	An Evaluation of Clinicopathological Correlation and Outcome of Human Epidermal Growth Factor Receptor 2 Subgroups Reclassified According to the Latest ASCO/CAP Guideline. <i>Clinical Breast Cancer</i> , 2022, 22, e114-e122.	1.1	4
2	Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes. <i>Oncologist</i> , 2022, 27, e313-e327.	1.9	14
3	Fine needle aspiration cytology of metastatic carcinomas with papillary architecture: A systemic assessment of clinical, cytological and immunohistochemical parameters. <i>Cytopathology</i> , 2022, 33, 328-343.	0.4	7
4	Associations between Preserved Foods and Breast Cancer Risk in Hong Kong Chinese Women. <i>Cancer Prevention Research</i> , 2022, 15, 497-507.	0.7	2
5	Papillary lesions of the breast – review and practical issues. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 344-354.	1.0	3
6	Analysis of recurrent molecular alterations in phyllodes tumour of breast: insights into prognosis and pathogenesis. <i>Pathology</i> , 2022, 54, 678-685.	0.3	2
7	INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer. <i>Pathology</i> , 2021, 53, 170-178.	0.3	18
8	Re: INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer: author reply. <i>Pathology</i> , 2021, 53, 293-294.	0.3	0
9	Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. <i>Modern Pathology</i> , 2021, 34, 1062-1073.	2.9	17
10	Papillary lesions of the breast: A systematic evaluation of cytologic parameters. <i>Cancer Cytopathology</i> , 2021, 129, 649-661.	1.4	10
11	SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 339-347.	1.1	9
12	The International Academy of Cytology Yokohama System for Reporting Breast Cytopathology showed improved diagnostic accuracy. <i>Cancer Cytopathology</i> , 2021, 129, 852-864.	1.4	11
13	Clinicopathologic and genetic features of metaplastic breast cancer with osseous differentiation: a series of 6 cases. <i>Breast Cancer</i> , 2021, 28, 1100-1111.	1.3	2
14	Tumor Microenvironment in Breast Cancer – Updates on Therapeutic Implications and Pathologic Assessment. <i>Cancers</i> , 2021, 13, 4233.	1.7	72
15	Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients. <i>Human Genetics and Genomics Advances</i> , 2021, 3, 100076.	1.0	3
16	Molecular analysis of TCGA breast cancer histologic types. <i>Cell Genomics</i> , 2021, 1, 100067.	3.0	37
17	AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 18.	1.1	19
18	Spindle cell lesions of the breast: diagnostic issues. <i>Diagnostic Histopathology</i> , 2020, 26, 76-87.	0.2	2

#	ARTICLE	IF	CITATIONS
19	Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 11-21.	1.1	22
20	The significance of highlighting the oestrogen receptor low category in breast cancer. <i>British Journal of Cancer</i> , 2020, 123, 1223-1227.	2.9	24
21	Core needle biopsy diagnosis of fibroepithelial lesions of the breast: a diagnostic challenge. <i>Pathology</i> , 2020, 52, 627-634.	0.3	16
22	Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. <i>British Journal of Cancer</i> , 2020, 123, 1665-1672.	2.9	26
23	SALL4 promotes tumor progression in breast cancer by targeting EMT. <i>Molecular Carcinogenesis</i> , 2020, 59, 1209-1226.	1.3	19
24	The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas. <i>Oncologist</i> , 2020, 25, e1318-e1329.	1.9	19
25	Axillary Nodal Metastasis with Papillary Morphology: An Uncommon Origin. <i>Acta Cytologica</i> , 2020, 64, 612-616.	0.7	0
26	Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 799-811.	2.0	10
27	Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups. <i>Clinical Breast Cancer</i> , 2020, 20, 253-261.e7.	1.1	6
28	Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. <i>Histopathology</i> , 2020, 77, 936-948.	1.6	24
29	Papillary Lesions of the Breast (IDP, IDPC, EPC, SPC). , 2019, , 145-157.		0
30	DNA Methylation Markers for Breast Cancer Detection in the Developing World. <i>Clinical Cancer Research</i> , 2019, 25, 6357-6367.	3.2	21
31	ASO Author Reflections: Resolving the Challenges in the Management of Mammary Phyllodes Tumor. <i>Annals of Surgical Oncology</i> , 2019, 26, 774-775.	0.7	0
32	The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology. <i>Acta Cytologica</i> , 2019, 63, 257-273.	0.7	71
33	Predicting Outcome in Mammary Phyllodes Tumors: Relevance of Clinicopathological Features. <i>Annals of Surgical Oncology</i> , 2019, 26, 2747-2758.	0.7	23
34	Diagnostic upgrade of atypical ductal hyperplasia of the breast based on evaluation of histopathological features and calcification on core needle biopsy. <i>Histopathology</i> , 2019, 75, 320-328.	1.6	15
35	Cytologic diagnosis of metastatic malignant phyllodes tumor of the breast in pleural effusion. <i>Diagnostic Cytopathology</i> , 2019, 47, 599-602.	0.5	5
36	Expression of biomarkers in the <sc>AKT</sc> pathway correlates with malignancy and recurrence in phyllodes tumours of the breast. <i>Histopathology</i> , 2019, 74, 567-577.	1.6	5

#	ARTICLE	IF	CITATIONS
37	The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes. <i>Cancer Research and Treatment</i> , 2019, 51, 706-717.	1.3	10
38	Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast. <i>Scientific Reports</i> , 2018, 8, 3881.	1.6	18
39	Papillary lesions of the breast. <i>Diagnostic Histopathology</i> , 2018, 24, 64-70.	0.2	4
40	GATA-3 is superior to GCDP-15 and mammaglobin to identify primary and metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 25-32.	1.1	48
41	Coexistence of Ductal Carcinoma Within Mammary Phyllodes Tumor: A Review of 557 Cases From a 20-year Region-wide Database in Hong Kong and Southern China. <i>Clinical Breast Cancer</i> , 2018, 18, e421-e425.	1.1	16
42	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018, 72, 1075-1083.	1.6	25
43	Amyloid Precursor Protein Is Associated with Aggressive Behavior in Nonluminal Breast Cancers. <i>Oncologist</i> , 2018, 23, 1273-1281.	1.9	13
44	Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer. <i>EBioMedicine</i> , 2018, 38, 89-99.	2.7	33
45	Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication. <i>Journal of Clinical Pathology</i> , 2018, 71, 1084-1089.	1.0	9
46	CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer. <i>Journal of Clinical Pathology</i> , 2018, 71, 1007-1014.	1.0	16
47	Atypical aspirates of the breast: a dilemma in current cytology practice. <i>Journal of Clinical Pathology</i> , 2017, 70, 1024-1032.	1.0	17
48	Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers. <i>Oncologist</i> , 2017, 22, 487-490.	1.9	18
49	PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 19-30.	1.1	86
50	Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers. <i>Oncologist</i> , 2017, 22, 1316-1324.	1.9	67
51	Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis. <i>Scientific Reports</i> , 2017, 7, 6752.	1.6	11
52	Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 4042-4050.	0.7	30
53	Doublecortin-like kinase 1 expression associates with breast cancer with neuroendocrine differentiation. <i>Oncotarget</i> , 2016, 7, 1464-1476.	0.8	32
54	Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes. <i>Journal of Clinical Pathology</i> , 2016, 69, 890-898.	1.0	18

#	ARTICLE	IF	CITATIONS
55	Lymphocyte subsets contribute to the degree of lobulitis and ductitis in sclerosing lymphocytic lobulitis of the breast. <i>Journal of Clinical Pathology</i> , 2016, 69, 527-532.	1.0	4
56	Hyaluronan synthase 2 is an adverse prognostic marker in androgen receptor-negative breast cancer. <i>Journal of Clinical Pathology</i> , 2016, 69, 1055-1062.	1.0	7
57	Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 806-814.	1.2	116
58	⁸ CD8 ⁺ tumor-infiltrating lymphocytes contribute to spontaneous "healing" in ² HER2-positive ductal carcinoma in situ. <i>Cancer Medicine</i> , 2016, 5, 1607-1618.	1.3	28
59	Pathological criteria and practical issues in papillary lesions of the breast " a review. <i>Histopathology</i> , 2016, 68, 22-32.	1.6	37
60	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. <i>Histopathology</i> , 2016, 68, 45-56.	1.6	37
61	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016, 68, 5-21.	1.6	329
62	FGFR1 is an adverse outcome indicator for luminal A breast cancers. <i>Oncotarget</i> , 2016, 7, 5063-5073.	0.8	24
63	MicroRNA's are differentially deregulated in mammary malignant phyllodes tumour. <i>Histopathology</i> , 2015, 67, 294-305.	1.6	9
64	¹ GATA-binding protein 3, gross cystic disease fluid protein ¹⁵ and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups. <i>Histopathology</i> , 2015, 67, 96-105.	1.6	16
65	Reply to the letter to the editor: A rare case of breast cancer showing distinct ¹ TTF nuclear expression: small-cell carcinoma or not?. <i>Histopathology</i> , 2015, 66, 753-754.	1.6	1
66	Is BECN1 a Target Gene of Chromosome 17q21 Alteration in Breast Cancer?. <i>EBioMedicine</i> , 2015, 2, 190-191.	2.7	1
67	Breast Cancers with Brain Metastases. , 2015, , 113-119.		0
68	Bcl2 and Ki67 refine prognostication in luminal breast cancers. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 631-643.	1.1	13
69	Anterior Gradient 2 is a Poor Outcome Indicator in Luminal Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3489-3496.	0.7	9
70	Associations of epithelial c-kit expression in phyllodes tumours of the breast. <i>Journal of Clinical Pathology</i> , 2015, 68, 808-811.	1.0	3
71	Identification of clinically relevant alterations in phyllodes tumor of the breast by amplicon-based next-generation sequencing. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 717-719.	1.1	8
72	Skull bone metastasis with adjacent leptomeningeal involvement from pleomorphic lobular carcinoma of the breast. <i>Histopathology</i> , 2015, 66, 1051-1053.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015, 163, 506-519.	13.5	1,485
74	Management of breast papillary lesions diagnosed in ultrasoundâ€guided vacuumâ€assisted and core needle biopsies. <i>Histopathology</i> , 2015, 66, 565-576.	1.6	44
75	Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis. <i>American Journal of Cancer Research</i> , 2015, 5, 3389-99.	1.4	10
76	Columnar cell-like changes in the male breast. <i>Journal of Clinical Pathology</i> , 2014, 67, 45-48.	1.0	10
77	Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 1-9.	1.1	27
78	Increased <sc>SOX</sc>2 expression in less differentiated breast carcinomas and their lymph node metastases. <i>Histopathology</i> , 2014, 64, 494-503.	1.6	31
79	Broad fibrovascular cores may not be an exclusively benign feature in papillary lesions of the breast: a cautionary note. <i>Journal of Clinical Pathology</i> , 2014, 67, 258-262.	1.0	11
80	Androgen Receptor Expression Shows Distinctive Significance in ER Positive and Negative Breast Cancers. <i>Annals of Surgical Oncology</i> , 2014, 21, 2218-2228.	0.7	60
81	A Novel Morphologic-Molecular Recurrence Predictive Model Refines Traditional Prognostic Tools for Invasive Breast Carcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2928-2933.	0.7	27
82	TTFâ€1 expression in breast carcinoma: an unusual but real phenomenon. <i>Histopathology</i> , 2014, 64, 504-511.	1.6	27
83	Immunohistochemistry in the diagnosis of papillary lesions of the breast. <i>Histopathology</i> , 2014, 65, 839-853.	1.6	25
84	CX3CL1 expression is associated with poor outcome in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 495-504.	1.1	46
85	Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. <i>Human Pathology</i> , 2013, 44, 1241-1250.	1.1	58
86	Fibrotic Focus in Breast Carcinomas: Relationship with Prognostic Parameters and Biomarkers. <i>Annals of Surgical Oncology</i> , 2013, 20, 2842-2849.	0.7	46
87	Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 311-322.	1.1	21
88	Increased lymphocytic infiltration in breast cancer correlated with molecular subtypes and HER2 gene amplification. <i>Histopathology</i> , 2013, 62, 963-965.	1.6	8
89	P-cadherin and vimentin are useful basal markers in breast cancers. <i>Human Pathology</i> , 2013, 44, 2782-2791.	1.1	12
90	Recent insights into the molecular pathogenesis of mammary phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2013, 66, 496-505.	1.0	32

#	ARTICLE	IF	CITATIONS
91	Papillary Lesions of the Breast. , 2013, , 103-121.		1
92	Carcinoma and Variants. , 2013, , 131-149.		2
93	Aspiration Techniques. , 2013, , 31-41.		2
94	Cytology of Epithelial Proliferative Lesions and High-Grade Ductal Carcinoma In Situ. , 2013, , 83-102.		0
95	Comparison of Aspiration and Core Needle Biopsy. , 2013, , 177-183.		0
96	Other Fibroepithelial Lesions. , 2013, , 73-82.		0
97	Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. Breast Cancer Research and Treatment, 2012, 136, 407-417.	1.1	64
98	Relationship between columnar cell changes and low-grade carcinoma in situ of the breastâ€™a cytogenetic study. Human Pathology, 2012, 43, 1924-1931.	1.1	8
99	Î±Bâ€™crystallin is a useful marker for triple negative and basal breast cancers. Histopathology, 2012, 61, 378-386.	1.6	27
100	E-cadherin expression in the epithelial components of mammary phyllodes tumors. Human Pathology, 2012, 43, 2117-2123.	1.1	16
101	Biopsy sampling of breast lesions: comparison of core needle- and vacuum-assisted breast biopsies. Breast Cancer Research and Treatment, 2012, 132, 917-923.	1.1	32
102	Involvement of Î±â€™and Î²â€™catenins and Eâ€™cadherin in the development of mammary phyllodes tumours. Histopathology, 2012, 61, 667-674.	1.6	17
103	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology, 2011, 24, 157-167.	2.9	545
104	Fine Needle Aspiration Cytology of the Breast: The Nonmalignant Categories. Pathology Research International, 2011, 2011, 1-8.	1.4	48
105	Increased alphaâ€™crystallin expression in mammary metaplastic carcinomas. Histopathology, 2011, 59, 247-255.	1.6	18
106	Epidermal growth factor receptor gene amplification and protein overexpression in basalâ€™like carcinoma of the breast. Histopathology, 2011, 59, 264-273.	1.6	17
107	Reduced numbers of regulatory T cells in breast carcinoma with medullary features. Histopathology, 2011, 59, 345-349.	1.6	4
108	Phyllodes tumours of the breast - differentiating features in core needle biopsy. Histopathology, 2011, 59, 600-608.	1.6	41

#	ARTICLE	IF	CITATIONS
109	A subset of breast cancer predisposes to brain metastasis. <i>Medical Molecular Morphology</i> , 2011, 44, 15-20.	0.4	42
110	Phyllodes tumor of the breast: an update. <i>Breast Cancer</i> , 2010, 17, 29-34.	1.3	71
111	Diagnosing breast lesions by fine needle aspiration cytology or core biopsy: which is better?. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 1-8.	1.1	60
112	Correlation of biomarkers in head and neck squamous cell carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2010, 143, 795-800.	1.1	16
113	Papillary lesions of the breast—accuracy of core biopsy. <i>Histopathology</i> , 2010, 56, 481-488.	1.6	30
114	Atypia in fine needle aspirates of breast lesions. <i>Journal of Clinical Pathology</i> , 2010, 63, 585-591.	1.0	13
115	Predictors of invasion in needle core biopsies of the breast with ductal carcinoma in situ. <i>Modern Pathology</i> , 2010, 23, 737-742.	2.9	27
116	Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 441-448.	1.1	57
117	Breast cancer in the elderly: a histological assessment. <i>Histopathology</i> , 2009, 55, 441-451.	1.6	14
118	HER2 Expression Predicts Improved Survival in Patients with Cervical Node-Positive Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2009, 141, 467-473.	1.1	15
119	Inflammatory pseudotumors of the central nervous system. <i>Human Pathology</i> , 2009, 40, 1611-1617.	1.1	69
120	Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. <i>Pathology</i> , 2009, 41, 105-117.	0.3	35
121	The role of immunohistochemistry in the differential diagnosis of breast lesions. <i>Pathology</i> , 2009, 41, 68-76.	0.3	62
122	Spindle cell lesions of the breast—the pathologic differential diagnosis. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 199-207.	1.1	72
123	Intermediate to highly suspicious calcification in breast lesions: a radio-pathologic correlation. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 1-7.	1.1	59
124	Fine needle aspiration cytology of breast cancer in women aged 70 years and older. <i>Pathology</i> , 2008, 40, 573-579.	0.3	0
125	Malignant Cervical Lymphadenopathy: Diagnostic Accuracy of Diffusion-weighted MR Imaging. <i>Radiology</i> , 2007, 245, 806-813.	3.6	195
126	Fine needle aspiration cytology of invasive micropapillary carcinoma of the breast. <i>Pathology</i> , 2007, 39, 401-405.	0.3	14

#	ARTICLE	IF	CITATIONS
127	Strong Immunohistochemical Expression of Vascular Endothelial Growth Factor Predicts Overall Survival in Head and Neck Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 3558-3565.	0.7	47
128	Magnetic resonance imaging of breast lesions—a pathologic correlation. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 1-10.	1.1	41
129	In vivo proton magnetic resonance spectroscopy of breast lesions: an update. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 249-255.	1.1	53
130	p63 is useful in the diagnosis of mammary metaplastic carcinomas. <i>Pathology</i> , 2006, 38, 16-20.	0.3	70
131	Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2006, 60, 1051-1056.	1.0	12
132	Fine-needle aspiration cytology of metaplastic carcinoma of the breast. <i>Journal of Clinical Pathology</i> , 2006, 60, 529-533.	1.0	30
133	Fine needle aspiration cytology of dermatofibrosarcoma protuberans in the breast: a case report. <i>Pathology</i> , 2005, 37, 84-86.	0.3	7
134	Cytokeratins in Papillary Lesions of the Breast. <i>American Journal of Surgical Pathology</i> , 2005, 29, 625-632.	2.1	83
135	Sonographic, Mammographic, and Histopathologic Correlation of Symptomatic Ductal Carcinoma In Situ. <i>American Journal of Roentgenology</i> , 2004, 182, 101-110.	1.0	99
136	Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters. <i>Modern Pathology</i> , 2004, 17, 568-572.	2.9	70
137	Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. <i>Modern Pathology</i> , 2004, 17, 827-831.	2.9	69
138	Relationship between lesion size and signal enhancement on subtraction fat-suppressed MR imaging of the breast. <i>Magnetic Resonance Imaging</i> , 2004, 22, 1259-1264.	1.0	5
139	Fine-needle aspiration cytology of pseudoangiomatous stromal hyperplasia of the breast. <i>Diagnostic Cytopathology</i> , 2004, 30, 353-355.	0.5	13
140	The significance of the Wnt pathway in the pathology of human cancers. <i>Pathology</i> , 2004, 36, 120-128.	0.3	246
141	Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: A multicenter study of 185 cases. <i>Human Pathology</i> , 2004, 35, 1053-1057.	1.1	65
142	Granulomatous mastitis: a clinicopathological review of 26 cases. <i>Pathology</i> , 2004, 36, 254-257.	0.3	99
143	Tuberculosis of the Nasopharynx: A Rare Entity Revisited. <i>Laryngoscope</i> , 2003, 113, 737-740.	1.1	42
144	Tumour Angiogenesis and p53 Protein Expression in Mammary Phyllodes Tumors. <i>Modern Pathology</i> , 2003, 16, 1007-1013.	2.9	39

#	ARTICLE	IF	CITATIONS
145	Characterization of Lesions of the Breast with Proton MR Spectroscopy: Comparison of Carcinomas, Benign Lesions, and Phyllodes Tumors. American Journal of Roentgenology, 2003, 181, 1267-1272.	1.0	89
146	Clonal analysis of bilateral mammary carcinomas by clinical evaluation and partial allelotyping. American Journal of Clinical Pathology, 2003, 120, 168-74.	0.4	22
147	Hormonal Receptors Expression in Epithelial Cells of Mammary Phyllodes Tumors Correlates With Pathologic Grade of the Tumor. American Journal of Clinical Pathology, 2002, 118, 522-526.	0.4	77
148	Breast Cancer: In Vivo Proton MR Spectroscopy in the Characterization of Histopathologic Subtypes and Preliminary Observations in Axillary Node Metastases. Radiology, 2002, 225, 190-197.	3.6	99
149	Increased p53 Protein Expression in Malignant Mammary Phyllodes Tumors. Modern Pathology, 2002, 15, 734-740.	2.9	70
150	Fine Needle Aspiration Cytologic Features of Mammary Phyllodes Tumors. Acta Cytologica, 2002, 46, 855-863.	0.7	36
151	Metachronous bilateral mammary metaplastic and infiltrating duct carcinomas: A molecular study for clonality. Human Pathology, 2002, 33, 677-679.	1.1	23
152	Fibromatosis of the Head and Neck Region. Otolaryngology - Head and Neck Surgery, 2001, 125, 516-519.	1.1	18
153	Sonographic Features of Primary Breast Cancer in Men. American Journal of Roentgenology, 2001, 176, 413-416.	1.0	67
154	Human Breast Lesions: Characterization with Contrast-enhanced in Vivo Proton MR Spectroscopy—Initial Results. Radiology, 2001, 220, 40-46.	3.6	179
155	MULTINUCLEATED STROMAL GIANT CELLS IN MAMMARY PHYLLODES TUMOURS. Pathology, 2001, 33, 153-156.	0.3	3
156	Fine-needle aspiration cytology of breast carcinoma with endocrine differentiation. Cancer, 2000, 90, 286-291.	2.0	25
157	A comparative study of diagnostic accuracy in 3026 pleural biopsies and matched pleural effusion cytology with clinical correlation. Cancer Medicine, 0, , .	1.3	8